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Abstract
Genetics has proven to be a powerful approach in neurodegenerative diseases research, resulting in 
the identification of numerous causal and risk variants. Previously, we introduced the NeuroX 
Illumina genotyping array, a fast and efficient genotyping platform designed for the investigation 
of genetic variation in neurodegenerative diseases. Here, we present its updated version, named 
NeuroChip. The NeuroChip is a low cost, custom-designed array containing a tagging variant 
backbone of about 306,670 variants complemented with a manually curated custom content 
comprised of 179,467 variants implicated in diverse neurological diseases, including Alzheimer's 
disease, Parkinson's disease, Lewy body dementia, amyotrophic lateral sclerosis, frontotemporal 
dementia, progressive supranuclear palsy, corticobasal degeneration and multiple system atrophy. 
The tagging backbone was chosen because of the low cost and good genome-wide resolution; the 
custom content can be combined with other backbones, like population or drug development 
arrays. Using the NeuroChip, we can accurately identify rare variants and impute over 5.3 million 
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common SNPs from the latest release of the Haplotype Reference Consortium. In summary, we 
describe the design and usage of the NeuroChip array, and show its capability for detecting rare 
pathogenic variants in numerous neurodegenerative diseases. The NeuroChip has a more 
comprehensive and improved content, which makes it a reliable, high-throughput, cost-effective 
screening tool for genetic research and molecular diagnostics in neurodegenerative diseases.
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Genotyping; NeuroX; NeuroChip; Genetic Screening; Neurodegeneration
1. Introduction
Neurodegenerative diseases are a major burden to the aging world population and currently 
these diseases are incurable and irreversible. Common and rare genetic alterations in many 
genes have been identified as disease-causing or contributing to the development of 
neurodegeneration (Naj et al., 2017, Singleton and Hardy, 2016). To date, there are four 
main uses of genetics: 1) to confirm a clinical diagnosis by identifying a causal mutation, 2) 
to identify risk variants and disease modifiers that influence risk for disease, 3) to increase 
knowledge of the molecular pathobiology of disease in the hopes of identifying therapeutic 
targets, and 4) to improve patient selection for pathway-specific clinical trial design. A 
reliable, high-throughput and cost-effective platform that can rapidly conduct these functions 
could therefore be immensely valuable to the field.
Previously, we presented the NeuroX array, which was a collaborative effort with the 
objective of designing a genotyping platform that would allow rapid genetic characterization 
of samples in the context of genetic mutations and risk factors associated with common 
neurodegenerative diseases (Nalls et al., 2015). This was an exonic array (or exome chip) 
based on the Infinium Human Exome Beadchip v1.1 containing 242,901 exome-focused 
variants as well as 24,706 custom variants focusing on neurological diseases. The NeuroX 
array has already been successfully used in dozens of studies (Barber et al., 2017, 
Carrasquillo et al., 2016, Ghani et al., 2015, Nalls et al., 2016, Rosenthal et al., 2016). 
However, due to the backbone's focus on rare exonic variation, common non-exonic variants 
were largely missed, resulting in a modest genome-wide resolution and only partial capture 
of the known low frequency exonic variation. Additionally, the number of genotype-
phenotype associations and pathogenic variants keeps expanding, so there was a continued 
need for updating this useful platform. Here, we report on an updated version of NeuroX, 
named NeuroChip. The NeuroChip backbone is based on a genome-wide genotyping array 
(Infinium HumanCore-24 v1.0) containing 306,670 tagging variants and a custom content 
that has been updated and extended with neurodegenerative disease-related custom content 
consisting of 179,467 variants. This backbone was chosen because of the low cost and good 
genome-wide resolution. This backbone is flexible and other arrays can be used with this 
custom content, such as population or drug development arrays (Infinium Multi-Ethnic, 
Infinium DrugDev). The NeuroChip allows to accurately identify rare neurodegenerative 
candidate variants and impute over 5.3 million common variants. Its approximate cost of ∼
$40 per sample is a fraction of the price of next-generation whole exome or whole genome 
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sequencing, and therefore provides a valuable, high-throughput screening tool for loci and 
variants implicated in neurodegenerative diseases. Further, this array can be used as a tool to 
prioritize samples for more expensive genome sequencing approaches.
2. Methods
2.1 NeuroChip array design
The backbone of the array, the Infinium HumanCore-24 v1.0, contains 306,670 highly 
informative tagging SNPs which can be used for high-throughput and high-quality 
imputation of genome-wide variants across diverse populations (Illumina). In addition, the 
chip contains 179,467 custom disease-associated variants (Table 1) covering 
neurodegenerative diseases including: Alzheimer's disease (AD), Parkinson's disease (PD), 
Lewy body dementia (LBD), frontotemporal dementia (FTD), amyotrophic lateral sclerosis 
(ALS), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple 
system atrophy (MSA). The custom-content has been curated by members of the 
International Parkinson's Disease Genomics Consortium (IPDGC) and the Comprehensive 
Unbiased Risk factor Assessment for Genetics and Environment in Parkinson disease 
(COURAGE-PD) consortium to include common variants and rare mutations implicated in 
neurological diseases as reported in the Human Gene Mutation Database (HGMD 
Professional 2016.4, QIAGEN), the NHGRI GWAS Catalog (www.ebi.ac.uk/gwas/), the 
Online Mendelian Inheritance in Man (OMIM) database (www.ncbi.nlm.nih.gov/omim/), 
the Parkinson's Disease Mutation Database (www.molgen.vib-ua.be/PDMutDB), the 
Alzheimer's Disease and Frontotemporal Dementia Database (www.molgen.ua.ac.be/
admutations/), and based on literature review as well as own data; particularly in the latter 
case, collaborators submitted variants that were identified in multiple ongoing (or 
completed) unpublished projects, including variants from genome-wide association (GWA), 
whole exome, whole genome, targeted sequencing studies and systems biology studies. See 
Supplementary Table 1 for the complete content of the NeuroChip array.
2.2 NeuroChip array genotyping
We genotyped a cohort of 273 controls as per the manufacturer's instructions (Illumina) to 
generate pilot NeuroChip data. These samples have been collected by the North American 
Brain Expression Consortium (NABEC) and described elsewhere (Hernandez et al., 2012). 
In total, 183 males and 90 females were included. All samples were obtained from North 
American brain banks; included subjects reported European ancestry and had no reported 
neurological disease. To assess the reproducibility of the NeuroChip, we genotyped 15 
samples twice in separate experiments.
Raw data files were imported into GenomeStudio (version 2.0, Illumina). For initial quality 
control, we confirmed accurate, high quality genotyping using a call rate threshold of > 
95%. We reclustered the samples using a GenCall threshold of 0.15 and recalled all variants. 
The genotyping cluster file based on ∼3,500 individuals of ongoing projects is available in 
the Supplementary Materials (Supplementary File 1). The mean call rate post-reclustering 
was 0.992 (range: 0.954-0.995). The data were exported from GenomeStudio using the 
Illumina-to-PLINK module 2.1.4 and imported into PLINK (version 1.90) (Chang et al., 
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2015). Next, we checked individuals for discrepancies between reported sex and genotypic 
sex, cryptic relatedness (PIHAT <0.05), and heterogeneity contamination, and found that no 
samples failed this quality control step.
2.3 NeuroChip content annotation
Annotation of the NeuroChip content was performed using ANNOVAR (Wang et al., 2010). 
For each variant, a gene-based annotation, in silico impact scores, and frequencies from 
public databases were obtained. To predict the impact scores, the following algorithms were 
used: SIFT (Kumar et al., 2009), Polyphen-2 (Adzhubei et al., 2010), and CADD (Kircher et 
al., 2014). Population frequencies were obtained from the Exome Aggregation Consortium 
(version 0.3.1) (http://exac.broadinstitute.org/) containing 60,706 individuals. Additionally, 
all variants were investigated for their presence in the Human Gene Mutation Database 
(HGMD, accessed 20 December 2016). Variants associated with a common 
neurodegenerative syndrome (AD, ALS, FTD and PD) were manually curated and are 
summarized in Supplementary Table 2.
2.4 NeuroChip content imputation
After confirming high-quality genotyping (call rate >95%) and European ancestry in all 
individuals (based on 1000Genomes clustering) (Genomes Project et al., 2015), we 
performed imputation using the Michigan imputation server, according to established 
guidelines (https://imputationserver.sph.umich.edu) (Das et al., 2016). In brief, genotypes 
were prepared for imputation using provided scripts (HRC-1000G-check-bim.pl), which 
compares variant ID, strand, and allele frequencies to the haplotype reference panel (HRC 
version r1.1, April 2016) (McCarthy et al., 2016). A total of 332,015 autosomal SNPs were 
submitted to the Imputation Server using ShapeIT (v2.r790).
2.5 APOE allele genotyping
To determine the accuracy of APOE allele predictions, we performed Taqman genotyping of 
two nonsynonymous APOE SNPs (rs7412 and rs429358) on an Applied Biosystems Vii A 7 
RealTime PCR System using an established protocol (Federoff et al., 2012). 272 out of 273 
control samples had sufficient DNA for genotyping. Allelic discrimination was conducted 
using QuantStudio software (version 1.3, Thermo Fisher Scientific, Carlsbad, CA, USA). 
Taqman genotype results were then compared to the corresponding results for the same 
SNPs generated using the NeuroChip. Given the importance of APOE, NeuroChip was 
designed so that rs7412 is genotyped by four separate probes (three of which performed 
well: rs7412, seq-rs7412-B1, seq-rs7412-B3). Similarly, rs429358 was genotyped by five 
separate bead probes (two of which performed well: seq-rs429358-T2, seq-rs429358-T3). 
This redundancy ensures accurate APOE genotyping by the NeuroChip platform.
3. Results
3.1 NeuroChip content overview
In total, the NeuroChip array contains 473,442 autosomal variants, 11,840 sex chromosomal 
variants, and 160 mitochondrial variants. Additionally, 16,274 NeuroChip variants detect 
small insertions or deletions (Table 1). The overlap between NeuroX and NeuroChip is small 
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(n= 19,289 variants) due to the difference in the design of the backbone; the NeuroX array is 
focused on exonic content, whereas the NeuroChip is focused on genome wide tagging 
content.
3.2 NeuroChip pathogenic variant content
In total, the NeuroChip harbors 8,086 disease-associated variants that are included in 
HGMD, a professionally curated database of published genetic variants that have been 
linked to inherited human diseases (neurological and non-neurological). The NeuroChip 
HGMD content includes 1,233 variants (1,202 SNPs and 31 indels) linked to common 
neurodegenerative syndromes (see Supplementary Figure 1 for a comparison between 
NeuroX and NeuroChip). In this content, after manually curation, 601 variants are 
associated with ALS or FTD, 348 with PD, and 284 with AD. Figure 1 shows the number of 
disease-associated variants per gene covered in common neurodegenerative syndromes 
based on the HGMD database content. Detailed, manually curated and annotated variant lists 
for the abovementioned neurodegenerative disease categories are documented in 
Supplementary Table 2. These annotated lists can be used as filters to quickly screen for 
known mutations and risk variants.
3.3 NeuroChip genotyping results
Genotyping reproducibility—Of the 15 technical replicates, all samples yielded high 
quality, reproducible genotyping results. The mean concordance rate per technical replicate 
was 0.9996 (range=0.9991-0.9999); on average, 190 variants (range=27-435) differed per 
technical replicate (0.04% of the total included variants on the array). Across the 15 
technical replicates, 1,978 unique variants were discordant, of which 749 (37.9%) were from 
the backbone and 1,229 (62.1%) were from the custom content (Supplementary Table 3).
Imputation—Imputation of autosomal variants was performed on a series of 273 European 
descent individuals using the haplotype reference panel (McCarthy et al., 2016) containing 
39,235,157 variants, all with an estimated minor allele count of >= 5 in 32,488 individuals. 
Initial pre-imputation filtering of the NeuroChip data (including removing duplicates and 
non-overlapping variants, switch strands, and updating position) resulted in 332,015 
variants. After imputation, 11,879,345 variants were obtained with an imputation R2 of > 
0.30. Filtering based on MAF > 0.05, Hardy-Weinberg Equilibrium p-value of > 1e-6 
resulted in 5,316,028 variants. In this imputed dataset, we successfully identified 22 of 26 
PD risk alleles and 19 of the 21 AD GWA SNPs (Lambert et al., 2013, Nalls et al., 2014).
Genotype accuracy—GenTrain scores were calculated for all NeuroChip variants using 
GenomeStudio (version 2, lllumina). The GenTrain score is a statistical score based on the 
shapes of the different allelic clusters and their relative distance to each other (Illumina). 
Typically, GenTrain scores > 0.7 are considered high quality genotypes. Previously, 
GenTrain scores of the NeuroX showed that genotyping quality in the custom content was 
lower compared to the backbone (Nalls et al., 2015). However, preliminary NeuroChip data 
from several ongoing projects (based on ∼3,500 individuals) reveals that the backbone and 
the custom content have a high comparable average score (0.819 and 0.820, respectively), 
indicating high genotyping accuracy (Supplementary Figures 2 & 3).
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Validation of APOE genotyping—APOE alleles are important genetic risk factors for 
both AD and LBD, but genotyping of this region is complicated by high GC content 
(Singleton et al., 2002, Strittmatter and Roses, 1996). For this reason, we chose to validate 
the accuracy of APOE allele genotyping by comparing Taqman results with genotype 
predictions from the NeuroChip (Supplementary Table 4). Taqman genotyping for rs7412 
and rs429358 was successful in all 272 samples. NeuroChip genotyping for both SNPs was 
successful in 265 out of these 272 controls. Five samples were discordant for APOE allele 
genotyping between Taqman and NeuroChip due to relatively low quality genotype calls in 
either the Taqman assay or the NeuroChip, representing 1.9% of our test cohort (n = 265 
samples). Overall, the performance of the NeuroChip for APOE genotyping was remarkable 
improved compared to the original NeuroX platform, which was unable to reliably detect 
rs7412 and rs429358 genotypes (Ghani et al., 2015, Nalls et al., 2015).
4. Discussion
The main goal was to develop a genotyping array that allows a rapid, high-throughput 
identification of common and rare single nucleotide variants in the human genome. 
Affordable screening of large cohorts for disease-associated variants allows for testing of 
polygenic inheritance that could explain the diversity of clinical and pathological 
characteristics of neurodegenerative diseases. The NeuroChip is estimated to cost ∼ $40/
sample, which is currently less than ∼ 10% and ∼ 5% of the cost of whole exome 
sequencing and whole genome sequencing, respectively.
We have designed, implemented, and validated the NeuroChip array platform for high 
throughput genotyping. However, it is important to recognize the limitations of this 
approach. Like all genotyping arrays, NeuroChip does not detect novel sequence changes. It 
is also not possible to genotype variants in complex genomic regions (e.g. due to 
pseudogenes) or to identify repeat expansions due to the difficulty in designing reliable 
probes. Nevertheless, every effort was made to improve genotyping calling in NeuroChip. 
For example, it was recognized that the APOE locus performed poorly on the original 
NeuroX platform (Ghani et al., 2015). Given the importance of this genomic region in 
neurodegeneration, the revised NeuroChip probe design included multiple probes for SNPs 
in this region. This led to reliable APOE allele calling with a concordance rate of 98.1% 
between NeuroChip and Taqman.
In conclusion, we describe the design and implementation of the NeuroChip array, which 
has a more comprehensive and improved content compared to NeuroX. This versatile 
genotyping platform provides the community with a novel tool that can be used in clinical 
and research settings. In a clinical setting, it is possible to rapidly screen patients for a large 
number of known pathogenic variants, and in a research setting cost-effective and high-
throughput detection of common and rare variants provides opportunities to perform several 
large-scale analyses, including GWAS, burden tests and genetic risk scores calculations
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Blauwendraat et al. Page 7
Neurobiol Aging. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
References
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server 
for predicting damaging missense mutations. Nat Methods. 2010; 7(4):248–9. [PubMed: 20354512] 
Barber IS, Braae A, Clement N, Patel T, Guetta-Baranes T, Brookes K, et al. Mutation analysis of 
sporadic early-onset Alzheimer's disease using the NeuroX array. Neurobiol Aging. 2017; 49:215 
e1-e8.
Carrasquillo MM, Barber I, Lincoln SJ, Murray ME, Camsari GB, Khan Q, et al. Evaluating 
pathogenic dementia variants in posterior cortical atrophy. Neurobiol Aging. 2016; 37:38–44. 
[PubMed: 26507310] 
Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to 
the challenge of larger and richer datasets. Gigascience. 2015; 4:7. [PubMed: 25722852] 
Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A, et al. Next-generation genotype 
imputation service and methods. Nat Genet. 2016; 48(10):1284–7. [PubMed: 27571263] 
Federoff M, Jimenez-Rolando B, Nalls MA, Singleton AB. A large study reveals no association 
between APOE and Parkinson's disease. Neurobiol Dis. 2012; 46(2):389–92. [PubMed: 22349451] 
Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global 
reference for human genetic variation. Nature. 2015; 526(7571):68–74. [PubMed: 26432245] 
Ghani M, Lang AE, Zinman L, Nacmias B, Sorbi S, Bessi V, et al. Mutation analysis of patients with 
neurodegenerative disorders using NeuroX array. Neurobiol Aging. 2015; 36(1):545 e9-14.
Hernandez DG, Nalls MA, Moore M, Chong S, Dillman A, Trabzuni D, et al. Integration of GWAS 
SNPs and tissue specific expression profiling reveal discrete eQTLs for human traits in blood and 
brain. Neurobiol Dis. 2012; 47(1):20–8. [PubMed: 22433082] 
Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for 
estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014; 46(3):310–5. 
[PubMed: 24487276] 
Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein 
function using the SIFT algorithm. Nat Protoc. 2009; 4(7):1073–81. [PubMed: 19561590] 
Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 
74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013; 
45(12):1452–8. [PubMed: 24162737] 
McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A reference panel of 
64,976 haplotypes for genotype imputation. Nat Genet. 2016; 48(10):1279–83. [PubMed: 
27548312] 
Naj AC, Schellenberg GD, Alzheimer's Disease Genetics C. Genomic variants, genes, and pathways of 
Alzheimer's disease: An overview. Am J Med Genet B Neuropsychiatr Genet. 2017; 174(1):5–26. 
[PubMed: 27943641] 
Nalls MA, Bras J, Hernandez DG, Keller MF, Majounie E, Renton AE, et al. NeuroX, a fast and 
efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol Aging. 
2015; 36(3):1605 e7-12.
Nalls MA, Keller MF, Hernandez DG, Chen L, Stone DJ, Singleton AB, et al. Baseline genetic 
associations in the Parkinson's Progression Markers Initiative (PPMI). Mov Disord. 2016; 31(1):
79–85. [PubMed: 26268663] 
Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale meta-analysis of 
genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet. 2014; 
46(9):989–93. [PubMed: 25064009] 
Rosenthal LS, Drake D, Alcalay RN, Babcock D, Bowman FD, Chen-Plotkin A, et al. The NINDS 
Parkinson's disease biomarkers program. Mov Disord. 2016; 31(6):915–23. [PubMed: 26442452] 
Singleton A, Hardy J. The Evolution of Genetics: Alzheimer's and Parkinson's Diseases. Neuron. 
2016; 90(6):1154–63. [PubMed: 27311081] 
Singleton AB, Wharton A, O'Brien KK, Walker MP, McKeith IG, Ballard CG, et al. Clinical and 
neuropathological correlates of apolipoprotein E genotype in dementia with Lewy bodies. Dement 
Geriatr Cogn Disord. 2002; 14(4):167–75. [PubMed: 12411758] 
Blauwendraat et al. Page 8
Neurobiol Aging. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci. 1996; 
19:53–77. [PubMed: 8833436] 
Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-
throughput sequencing data. Nucleic Acids Res. 2010; 38(16):e164. [PubMed: 20601685] 
Blauwendraat et al. Page 9
Neurobiol Aging. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Highlights
• NeuroChip is a genotyping chip for rapid screening of variants implicated in 
neurological disease
• This affordable and versatile array allows robust identification of common 
and rare variants
• NeuroChip is a high-throughput screening tool for genetic research and 
molecular diagnostics
• Here, we describe the design, implementation and validation of the 
NeuroChip
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Figure 1. Overview of the number of HGMD disease associated variants that are present on the 
NeuroChip
AD = Alzheimer's disease, ALS = amyotrophic lateral sclerosis, FTD = frontotemporal 
dementia, and PD = Parkinson's disease
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Table 1
Differences between NeuroX and the NeuroChip
Variant Description NeuroX NeuroChip Comparison
Total variants (pre-QC) 267,607 486,137 +218,530
Backbone 242,901 306,670 +63,769
Custom-content variants 24,706 179,467 +154,761
Indels 200 16,259 +16,059
Autosomal variants 261,477 473,442 +211,965
Coding variants 226,104 88,560 -137,544
Sex chromosomal variants 5,906 11,840 +5,934
Mitochondrial variants 219 160 -59
Variants with MAF < 0.05 219,093 227,448 +8,355
Variants with MAF < 0.001 179,500 154,953 -24,547
MAF = minor allele frequency
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